Indian Institute of Management, Bangalore (IIM-B) is announced the appointment of Dr. Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon Limited, as the Chairperson of its Board of Governors. She takes over from Mr. Mukesh D Ambani and became the first woman Chairperson of any IIM Board.
The USFDA approved Chelsea Therapeutics's product Northera capsules (droxidopa), orphan-product, for the treatment of neurogenic orthostatic hypotension (NOH) which is rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atro
Presently, the first line and second line antiretroviral therapy (ART) is given to HIV/AIDS patients free of cost in all ART Centres across the country. The Technical Resource Group on ART on 27th December, 2013 recommended providing third line antiretroviral therapy for HIV/AIDS patients through 10 centres of excellence across the country. The process for the same has been initiated at Department of AIDS Control.
The U.S. Food and Drug Administration expanded the approved use of Imbruvica™ which contains ibrutinib, for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy on Wednesday, 12 Feb, 2014. Imbruvica™ is manufactured by Pharmacyclics based at Sunnyvale, California.
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced on 11th feb, 2014 that the company was awarded U.S. Patent No. 8,647,626, entitled “Compositions Comprising TNF-specific Antibodies for Oral Delivery.”
For atherosclerotic cardiovascular disease risk reduction, American College of Cardiology and the American Heart Association guidelines recommend initiating moderate or high-intensity statin monotherapy as the firs
Mast Therapeutics, Inc., publicly traded biopharmaceutical company headquartered in San Diego, California, announced on 10th feb, 2014 that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure.
RSSDI Annual Scientific Meetings provide a wonderful opportunity to all of us, to meet and interact with each other and share our research, knowledge and clinical experience in all facets of diabetes care. RSSDI-2013 will be yet another enriching scientific experience, where we shall strive hard to meet the expectations of clinicians and researchers alike.
The Zydus Group announced a breakthrough in its research efforts with Lipaglyn TM (Saroglitazar), a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn TM is the first Glitazar to be approved anywhere in the world.
Gujarat has contributed significantly through acquisitions of foreign assets and by having export-led business models which has reflected in rising share in India’s pharma exports as well as industry turnover, reveals the ASSOCHAM.